1. Home
  2. Detail

@jo_dayto: Un rêve d'enfant devenu réalité 😌 Parfois, j'ai envie d’arrêter la moto, puis je me souviens... ça fait partie de moi ! @TriumphMotorcycles.france @NEXX Helmets @Shapeheart @Alpinestars #moto #triumph #daytona660 #fyp #biker

Jo_Dayto
Jo_Dayto
Open In TikTok:
Region: FR
Wednesday 26 August 2026 11:01:12 GMT
25511
3721
73
58

Music

Download

No Watermark .mp4 (0MB) No Watermark(HD) .mp4 (0MB) Watermark .mp4 (0MB) Music .mp3

Comments

herosfragile0
Jay-wook🥊🥊 :
J’ai compris BLINK j’me suis dit wshhh blink= fandom de blackpink
2026-09-07 19:03:11
1
elo_375
Eloïse❤️‍🔥🖤 :
Et tu as totalement raison les motards c’est vous les meilleurs
2026-08-28 00:59:05
6
dravx69
DravX :
Le porte plaque a fait 2 semaines et je l’ai changé 🤣
2026-08-27 06:51:13
3
aurore.a6
a. :
toujours croire en des rêves et vraiment belle 🥰
2026-08-28 18:23:08
4
leyrox13
Leyrox :
et yo ça va ? on peut te mp ? j'hésite a la prendre en a2, entre plusieurs moto en vrai. c'est possible d'avoir un retour de ta part sur la moto stp ?
2026-08-28 01:00:00
2
lova.c67
lova.c67 :
OUIIIII
2026-08-28 07:06:47
5
lova.c67
lova.c67 :
Tu fera attention la première photo tu t’es caché on es trop imposantes nous les booktok girl et motardes ✌😂
2026-08-28 07:07:36
3
yu1chiro_fan
E ꨄ🇧🇷🇵🇹 :
@𝐃𝐫𝐚𝐠𝐚𝐧𝐚 oui
2026-09-07 19:09:42
2
ange.dchu24
ange déchu 🐺 :
🥰👍
2026-09-07 18:42:42
1
ethancauvin2
Ethan :
🥰
2026-09-07 19:04:21
1
alphonse5785
EN 🦀 🇧🇷 :
🔥🔥🔥
2026-08-27 18:22:57
1
erin.sllr
Erin Sellier :
🔥
2026-08-26 11:26:40
1
jesslm9597
jessLM :
😍✌🏼
2026-08-26 11:02:47
1
To see more videos from user @jo_dayto, please go to the Tikwm homepage.

Other Videos

cách xem lỗi màn hình chờ của tướng mới Evita #evita #lienquan #lienquanmobile #AOV #xuhuong
cách xem lỗi màn hình chờ của tướng mới Evita #evita #lienquan #lienquanmobile #AOV #xuhuong


Hai cô Tiên nhất cho hạng nhất
Hai cô Tiên nhất cho hạng nhất
احمد شاه مسعود
احمد شاه مسعود
thank u korea 😭🇰🇷 @beautyofjoseon.id #bojsunscreen #bojaquafreshsunscreen #sunscreen #koreanskincare #glassskin
thank u korea 😭🇰🇷 @beautyofjoseon.id #bojsunscreen #bojaquafreshsunscreen #sunscreen #koreanskincare #glassskin
I have good news and bad news, and they are the same news. The good news: some of the most outrageously priced brand-name drugs in America are finally going generic, and that means we can get them cheap. Four big ones have flipped just this stretch. Nobody talks about it, so I will. Farxiga was the most exciting so far. It did not slowly drift down the way drugs usually do. The day it went generic, it got cheap instantly. There was one snag: a lot of insurance plans would not cover the cheap version. We have sold a ton of it anyway, so plenty of people quietly saved real money. Now today's drug: Humira. This one cost Medicare about $4.5 billion in 2024 alone. One drug. Then it finally got biosimilar competition, a whole shelf of them. And the market moved with the snap of a finger. Biosimilars went from 0.3% of the market in 2023, to 21% in 2024, to 82.4% in 2025. Here is where the good news becomes the bad news. When I say it moved with the snap of a finger, I mean somebody snapped it. The insurance companies and their PBMs sat down and decided which biosimilars they would cover. And guess which ones they picked. Not the best clinical option. Not the cheapest, and there are versions out there with 95% discounts. They picked their own white-label products. Express Scripts, CVS Caremark, and OptumRx excluded nearly all the non-house-brand biosimilars from their 2025 formularies. Think about what that means. They took one of the biggest drug markets in the world, and instead of letting the cheapest option win, they routed the money into products they own. In a normal competitive market, the low-cost product earns its place. That is not what happened here. And here is the part that should really get you. The patient did not choose. The doctor did not choose. The people with the actual medical knowledge, and the people it actually matters to, did not get a vote. But the patient is the one paying for it. It is not the insurance company's money they are moving around. It is yours. They quietly took over a market that you fund, then turned around and told you which medication you are allowed to take. That is the whole game in one story. That is why we fired them. No formulary tricks, no house-brand markup, no hidden middleman deciding your prescription for you. You see the real price and you decide. Head to forestparkpharmacy.com, look at the price checker, and transfer today to save. See ya. Sources: Drug Channels; PSG/Artemetrx 2026 Specialty Spend and Trend Report; Medicare Part D spending data.
I have good news and bad news, and they are the same news. The good news: some of the most outrageously priced brand-name drugs in America are finally going generic, and that means we can get them cheap. Four big ones have flipped just this stretch. Nobody talks about it, so I will. Farxiga was the most exciting so far. It did not slowly drift down the way drugs usually do. The day it went generic, it got cheap instantly. There was one snag: a lot of insurance plans would not cover the cheap version. We have sold a ton of it anyway, so plenty of people quietly saved real money. Now today's drug: Humira. This one cost Medicare about $4.5 billion in 2024 alone. One drug. Then it finally got biosimilar competition, a whole shelf of them. And the market moved with the snap of a finger. Biosimilars went from 0.3% of the market in 2023, to 21% in 2024, to 82.4% in 2025. Here is where the good news becomes the bad news. When I say it moved with the snap of a finger, I mean somebody snapped it. The insurance companies and their PBMs sat down and decided which biosimilars they would cover. And guess which ones they picked. Not the best clinical option. Not the cheapest, and there are versions out there with 95% discounts. They picked their own white-label products. Express Scripts, CVS Caremark, and OptumRx excluded nearly all the non-house-brand biosimilars from their 2025 formularies. Think about what that means. They took one of the biggest drug markets in the world, and instead of letting the cheapest option win, they routed the money into products they own. In a normal competitive market, the low-cost product earns its place. That is not what happened here. And here is the part that should really get you. The patient did not choose. The doctor did not choose. The people with the actual medical knowledge, and the people it actually matters to, did not get a vote. But the patient is the one paying for it. It is not the insurance company's money they are moving around. It is yours. They quietly took over a market that you fund, then turned around and told you which medication you are allowed to take. That is the whole game in one story. That is why we fired them. No formulary tricks, no house-brand markup, no hidden middleman deciding your prescription for you. You see the real price and you decide. Head to forestparkpharmacy.com, look at the price checker, and transfer today to save. See ya. Sources: Drug Channels; PSG/Artemetrx 2026 Specialty Spend and Trend Report; Medicare Part D spending data.

About

Legal